Lataa...

P07.02 Trials of a personalized peptide vaccine (ITK-1) for patients with recurrent or progressive glioblastoma (GBM)

Immunotherapy trials for glioblastoma (GBM) have some effects but the efficacy was limited, some because of the low immunogenicity and diverse antigens for GBMs. Personalized selection of suitable peptides for patients is one way to conquer this problem. We conducted serial series of clinical trials...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Fujimaki, T., Itoh, K., Terasaki, M., Narita, Y., Arakawa, Y., Sugiyama, K., Nishikawa, R., Aoki, T., Kumabe, T., Nagane, M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2017
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464231/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.187
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!